Myriad Genetics Shares Fall, Company Reports Earnings and CEO Change

Dow Jones

02-25

By Josh Beckerman

Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30.

The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance.

Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey & Co.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 24, 2025 17:49 ET (22:49 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514570781"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514570781\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514570781?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 06:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514570781","market":"nz","top_or_hot":-1,"title":"Myriad Genetics Shares Fall, Company Reports Earnings and CEO Change","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30. \n</p>\n<p>\n  The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance. \n</p>\n<p>\n  Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey &amp; Co. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 17:49 ET (22:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Shares Fall, Company Reports Earnings and CEO Change</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Shares Fall, Company Reports Earnings and CEO Change\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-25 06:49</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30. \n</p>\n<p>\n  The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance. \n</p>\n<p>\n  Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey &amp; Co. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 17:49 ET (22:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"萬基遺傳","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514570781","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514570781","pubTimestamp":1740437340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30.The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance.Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey & Co.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"Myriad Genetics股价下跌，公司报告收益和首席执行官变动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30. \n\n\n  The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance. \n\n\n  Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey & Co. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 17:49 ET (22:49 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1}}}